National Collegiate Inventors & Innovators Alliance, Inc.

National Collegiate Inventors & Innovators Alliance, Inc., doing business as Venturewell, is a Massachusetts-based nonprofit that operates as a federal prime contractor and grant recipient specializing in innovation program management, technology commercialization support, entrepreneurship training, and award administration across the National Institutes of Health and other civilian agencies. Venturewell competes in full-and-open (no set-aside) markets and has built a dominant footprint in NIH's Rapid Acceleration of Diagnostics (RADx) initiative, holding five indefinite-delivery contracts worth approximately $550 million in combined ceiling value.

Venturewell's federal customer concentration is heavily skewed toward NIH institutes. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) anchors the largest dollar share at $593.4 million across 21 awards, followed by the National Heart Lung and Blood Institute at $334.7 million across 31 awards. Together, these two NIH components represent the overwhelming majority of Venturewell's federal contract value. The Office of Logistics and Acquisition Operations carries $151.5 million on just two awards—both related to RADx award management. Beyond NIH, Venturewell holds significant federal grant positions with the National Science Foundation (28 awards, primarily cooperative agreements for I-Corps program operations and workshop facilitation) and the National Oceanic and Atmospheric Administration (climate resilience and ocean innovation accelerator programming). The Department of State, Department of Defense (DARPA), and the National Cancer Institute round out the active agency set.

Venturewell's prime contract vehicle portfolio centers on five large single-award indefinite-delivery contracts: the NIBIB Innovation Funnel Commercialization Center IDC ($139.6 million ceiling, through August 2027) and the NIBIB Innovation Funnel Award Management IDC ($100 million ceiling, through May 2026) together represent the foundation of Venturewell's near-term pipeline. A newly awarded RADx Award Management contract from NIH's Office of Logistics and Acquisition Operations carries a $150 million ceiling through August 2031. The National Heart Lung and Blood Institute's Innovation Funnel Award Management IDC ($99.9 million ceiling, through January 2028) and the RADx Clinical Evaluation Services IDC ($58.1 million ceiling, expired June 2023) round out the large vehicles. Task orders under these IDCs are typically $1 million to $50 million in firm fixed-price delivery orders. Venturewell also holds a GSA Multiple Award Schedule contract ($7 million ceiling, through July 2031) offering 21 labor categories spanning associate through senior technical advisor positions at $85–$375 per hour.

Recent representative contract work spans the RADx initiative's core functions: a $29.4 million delivery order (September 2026, through September 2030) for RADx Innovation Funnel for Health Technologies Commercialization Center operations at Frederick, Maryland; a $40.7 million order (September 2026, through September 2030) for RADx award management services at Amherst, Massachusetts; a $42.5 million RADx Innovation Funnel for COVID-19 Award Management order (June 2023, through May 2026); and a $21 million National Heart Lung and Blood Institute delivery order for RADx clinical evaluation services (June 2023, through June 2026). Venturewell also holds defense-sector work through DARPA: a $1.49 million Generative Optogenetics Independent Commercialization Consulting Group contract (June 2026, through December 2029) and a $999,354 SWITCH Program base award (January 2025, through January 2028). On the grant side, Venturewell is the prime recipient of a cooperative agreement with the National Science Foundation for I-Corps continuation and expansion of training and evaluation support (October 2023, through September 2027), managing entrepreneurship training for approximately 2,700 individual I-Corps participants. The organization also received a $100,000 Department of Energy cooperative agreement for water power accelerator design and gap assessment (November 2025, through September 2026) and holds a $1.35 million NOAA cooperative agreement for ocean-based climate resilience accelerator programming (January 2025, through December 2028).

On the grant sub-award side, Venturewell serves as a resource or evaluation core lead under awards held by Johns Hopkins University, Princeton University, Massachusetts General Hospital, and the University of Georgia, typically managing diverse networks of expert consultants and service providers to support innovation and commercialization in neurotech, agricultural, and engineering research contexts.

Activity has been volatile. Annual contract awards peaked at 19 in 2022, declined to 12 in 2024 and 7 in 2025, and rebounded to 8 in 2026. Fourteen awards carrying $38.3 million in combined potential value face ultimate completion in the next twenty-four months, signaling recompete exposure primarily around RADx clinical evaluation and award management tasks. SCI-reported invoicing totaled $307.9 million across fiscal years 2022–2025, with peak activity in FY2023 at $109.9 million. Derived government-paid hourly rates across prime SCI records span from $34.86/hr (10th percentile) to $11,887.74/hr (90th percentile), with a median of $1,061.53/hr reflecting the mix of administrative support labor, program management, and senior clinical evaluation consulting. Venturewell reports approximately 9.0 FTEs on SCI-reportable federal service contracts in FY2025. Across SCI-documented prime contracts, subcontractors account for an average of 7% of total contractor hours, with 130 named subcontractors engaged across the portfolio, indicating Venturewell operates primarily with internal delivery teams rather than relying on deep sub-contractor networks.

Venturewell explicitly frames its core capability as supporting over 5,800 innovation teams that have launched more than 4,300 ventures and raised more than $5.7 billion in downstream funding. The organization operates a national network of 400 coaches, industry experts, and active investors drawn from across 360+ universities and 47 states. Capability strengths center on diagnostic technology acceleration (particularly COVID-19, HIV, monkeypox, hepatitis C, endometriosis, and cancer screening diagnostics), entrepreneurship training (I-Corps, boot camps, accelerator curriculum design), award management and clinical evaluation service delivery, and ecosystem development for emerging technology sectors including renewable energy, ocean resilience, and life sciences.